Registry for Apomorphine-, L-Dopa-Infusiontherapy and Deep Brain Stimulation in Patients with Parkinson’s Disease

Conditions

G20.00

Stefanie T. Jost, Salima Aloui, Julian Evans, Keyoumars Ashkan, Anna Sauerbier et al. (97 authors)

JAMA Network Open2024-01-1831 citations

10.1001/jamanetworkopen.2023.52177

Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease

Anna Sauerbier, Philipp Alexander Loehrer, Stefanie T. Jost, Shania Heil, Jan Niklas Petry‐Schmelzer et al. (21 authors)

Journal of Neurology Neurosurgery & Psychiatry2021-09-1126 citations

10.1136/jnnp-2021-326131

Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease.

Dafsari HS, Reddy P, Herchenbach C, Wawro S, Petry-Schmelzer JN, Visser-Vandewalle V, Rizos A, Silverdale M, Ashkan K, Samuel M, Evans J, Huber CA, Fink GR, Antonini A, Chaudhuri KR, Martinez-Martin P, Timmermann L, IPMDS Non-Motor Symptoms Study Group.

2015-08-1981 citations

10.1016/j.brs.2015.08.005

Interventions

Group 1: Deep brain stimulation: demographic data, treatment application data and hardware and procedure associated side effects, motor and non-motor symptoms, quality of life Group 2: Intra-jejunal l

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with PD, diagnosed according to British Brain Bank criteria which are eligible for treatment with Apomorphine and intra-jejunal l-dopa infusion therapy and deep brain stimulation.

Exclusion criteria

Exclusion criteria: - Clinically significant irregularities in the MRI scan like, e.g., strokes, cerebellar atrophy, and tumors. - Clinically significant psychiatric diseases. - Clinicallly significant neuropsychological impairments.

Design outcomes

Primary

Measure	Time frame
Non-motor (Non-motor Symptom Scale) and quality of life (Parkinson's Disease Questionnaire)	—

Secondary

Measure	Time frame
Demographic data, treatment application data and hardware and procedure associated side effects, motor and non-motor symptoms	—

Countries

Germany, United Kingdom

Contacts

Public ContactLars Timmermann

Department of NeurologyUniversity Hospital Cologne

lars.timmermann at uk-koeln.de0049 221 478 7494

Outcome results

None listed